- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02541409
Directly Observed Therapy for HCV in Chennai, India (C-DOT)
Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a non-blinded randomized clinical trial with 50 participants randomized at a 1:1 allocation ratio to one of two treatment arms.
Arm 1: Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
Arm 2: Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
Pegylated-interferon alfa-2a (PEG) will be delivered subcutaneously once weekly. Sofosbuvir (SOF) and ribavirin (RBV) will be taken orally once daily for the entire study period.
The study will take place at the YR Gaitonde Centre for AIDS Research and Education (YRGCARE). YRG CARE is a non-profit medical and research institution in Chennai. YRGCARE Medical Centre provides medical care for more than 18,000 persons with HIV disease. Currently more than 8000 persons are receiving highly active antiretroviral therapy at the center.
Participants will be recruited from the YR Gaitonde Centre for Substance Abuse Research (YRGCSAR), which is affiliated with YRGCARE. The investigators will primarily recruit subjects from a cohort study of current and former people who inject drugs (PWID) that is ongoing at the same center. Eligible participants will be randomized to one of the two treatment arms after providing written informed consent. Treatment will be delivered directly to participants daily by field workers at a location of the participants choosing. Participants will be asked to visit the study clinic every four weeks during treatment and 12 weeks after completing treatment for additional study procedures. In addition, participants in Arm 1 will be asked to visit the clinic every week to receive their PEG injection.
The primary outcome is treatment completion. Secondary outcomes include SVR12, safety and tolerability and insulin resistance.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600113
- YR Gaitonde Centre for AIDS Research and Education
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing/able to provide consent
- Age ≥ 18
- Chronic HCV (HCV RNA positive)
- Resident of Chennai and can provide locator information
- If co-infected with HIV, must have CD4 (Cluster of Differentation 4) > 350 cells/mm3 and either: 1) ART naïve or 2) if on ART be on a tenofovir-containing regimen. If a participant's CD4 drops below 350 cells/μl (threshold for treatment in India), will have to initiate a tenofovir-containing regimen (current standard of care).
Participants must have the following at screening:
- Alanine Aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN)
- Aspartate Aminotransferase (AST) ≤ 10 x ULN
- Hemoglobin ≥ 12 g/dl for males and 11 g/dl for females
- International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR
- Albumin ≥ 3 g/dl
- Direct bilirubin ≤ 1.5 x ULN
- Creatinine clearance ≥ 60 ml/min (Cockgroft-Gault Equation)
- Alpha fetoprotein < 50 ng/ml
- Absolute neutrophil count (ANC) ≥ 1,500/μL
- Platelets ≥ 90,000/μL
- Thyroid stimulating hormone (TSH) ≤ ULN
A female subject is eligible if it is confirmed that she is:
- Not pregnant or nursing
- Of non-childbearing potential (i.e., women who have had hysterectomy, have both ovaries removed or medically documented ovarian failure, or are postmenopausal women > 50 years of age with cessation (for ≥12 months) of previously occurring menses
Of childbearing potential and negative urine pregnancy test prior to randomization and agree to one of the following from 3 weeks prior to Baseline/Day 1 until 6 months after the last dose of RBV.
- Complete abstinence from intercourse.
Or
• Consistent use of approved methods of birth control in addition to a male partner who correctly uses a condom from 3 weeks prior to Baseline/Day 1 until 6 months after the last dose of RBV.
- Male participants must agree to consistently and correctly use a condom. If their female partner is of childbearing potential, their partner must agree to use one of the study approved non-hormonal methods of birth control or a hormone-containing contraceptive, from the date of screening until 7 months after their last dose of RBV
- Male participants must agree to refrain from sperm donation for at least 7 months after the last dose of RBV.
- Of generally good health as determined by the investigator.
- Able to comply with the dosing instructions for study drug administration and willing to complete the study schedule of assessments.
Exclusion Criteria:
- Pregnant/nursing female or male with pregnant/nursing female partner.
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage, MELD<12)
- Prior hepatitis C treatment
- Infection with hepatitis B virus
- Chronic use of systematically administered immunosuppressive agents (e.g., prednisone equivalent >10 mg/day)
- Use of any prohibited concomitant medications within 28 days of the Baseline/Day 1 visit.
- Contraindications to RBV therapy or PEG/RBV
- Known hypersensitivity to RBV or PEG, the metabolites or formulation excipients
Additional exclusion criteria related to Aim 1 regimen
- Pre-existing significant psychiatric condition(s) including severe depression, severe bipolar disorder and schizophrenia. Other psychiatric disorders are permitted if the condition is well controlled with a stable treatment regimen for ≥ 1 year from screening.
- Presence of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis).
- History of clinical significant retinal disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SOF+PEG+RBV
Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
|
Direct acting antiviral agent used for the treatment of hepatitis C
Other Names:
Antiviral agent used for the treatment of hepatitis C
Other Names:
Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
Other Names:
|
Active Comparator: SOF+RBV
Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
|
Direct acting antiviral agent used for the treatment of hepatitis C
Other Names:
Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HCV Treatment Completion
Time Frame: 12 weeks from baseline for SOF+PEG+RBV and 24 weeks from baselne for SOF+RBV
|
The percentage of subjects that complete their course of treatment
|
12 weeks from baseline for SOF+PEG+RBV and 24 weeks from baselne for SOF+RBV
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained Virologic Response (SVR)
Time Frame: 24 weeks from baseline for SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV
|
The percentage of participants who achieve SVR as assessed by undetectable HCV RNA measured 12 weeks after treatment completion
|
24 weeks from baseline for SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV
|
Serious Adverse Events
Time Frame: 24 weeks from baseline SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV
|
Number of participants with treatment-related serious adverse events by laboratory tests and physician examination
|
24 weeks from baseline SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV
|
Change in Insulin Resistance
Time Frame: Difference from entry to 24 weeks for SOF+PEG+RBV and difference from entry to 36 weeks for SOF+RBV
|
Change in insulin resistance while on treatment by the homeostasis model assessment - insulin resistance (HOMA-IR).
HOMA-IR is calculated according to the formula (fasting insulin (microU/L)+fasting glucose (nmol/L)/22.5.
Fasting insulin and glucose measurements are obtained using whole blood.
|
Difference from entry to 24 weeks for SOF+PEG+RBV and difference from entry to 36 weeks for SOF+RBV
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sunil S Solomon, MBBS, PhD, MPH, Johns Hopkins School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis, Chronic
- Hepatitis
- Hepatitis C
- Hepatitis C, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Sofosbuvir
- Ribavirin
- Peginterferon alfa-2a
- Interferon alpha-2
Other Study ID Numbers
- R01DA02672
- R01DA026727 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C, Chronic
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Sofosbuvir
-
Assiut UniversityUnknown
-
University of California, San FranciscoCompletedHepatitis C | Transplantation Disease TransmissionUnited States
-
Icahn School of Medicine at Mount SinaiGilead SciencesCompletedHepatitis C | CryoglobulinemiaUnited States
-
Radboud University Medical CenterWithdrawnHCVNetherlands, Germany
-
Fondazione Italiana Linfomi ONLUSCompletedHepatitis C | Indolent B-cell LymphomaItaly
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Hepatitis C (Disorder)
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
Brigham and Women's HospitalRecruiting
-
Alexandria UniversityCompletedHepatocellular Carcinoma | Hepatitis C | Neoplasm Recurrence | Treatment ComplicationEgypt